Pre-eclampsia
Drug research and approvals for pre-eclampsia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 17, 2026, 140 studies of pre-eclampsia are recruiting on ClinicalTrials.gov, and Health Canada has authorized 2 drug trials for it since 2013.
- Recruiting worldwide: 140
- Trials authorized in Canada: 2
- FDA orphan approvals: 0
- EU medicines: 0
Recruiting Now
Newest start dates first, of 140 recruiting on ClinicalTrials.gov ↗- Ravulizumab in Pregnancies Complicated by Severe Hypertensive DisordersNCT06333652 · Phase 2 · Mayo Clinic · starts Apr 1, 2027
- Optimizing Preeclampsia Postpartum With Point-of-care UltrasoundNCT07167862 · Phase 4 · University of California, Irvine · starts Oct 26, 2026
- Oxford Luteal Dysfunction and Placental Insufficiency StudyNCT07072052 · Not reported · University of Oxford · starts Oct 23, 2026
- Community Health Worker Support to Lower Blood Pressure After a Pregnancy With High Blood PressureNCT07778966 · Not applicable · University of Alabama at Birmingham · starts Oct 19, 2026
- Vagal Stimulation Therapy and PreeclampsiaNCT06953115 · Not applicable · Fundación Internacional René Mey · starts Oct 15, 2026
- Role of Postpartum Furosemide in Recovery of Patients With Severe PreeclampsiaNCT07861685 · Not applicable · Lady Reading Hospital, Pakistan · starts Oct 1, 2026
- MH-Rx Study (Baby on Board: Check-in on You, Your Medication, & Your Blood Pressure)NCT07842341 · Not applicable · Texas Southern University · starts Sep 25, 2026
- Advancing Stillbirth Prevention Through Innovative Risk Evaluation (ASPIRE) Clinical StudyNCT07669935 · Not reported · Medicines360 · starts Sep 8, 2026
- Exercise to Improve Heart and Metabolic Health After Childbirth in Women at High Risk for PreeclampsiaNCT07921173 · Not applicable · Chinese University of Hong Kong · starts Sep 3, 2026
- Progesterone PreeclampsiaNCT07448597 · Phase 4 · Medical University of South Carolina · starts Aug 13, 2026
Drug Pipeline
19 in phase 3, 17 in phase 2, 6 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this condition- Aspirin
- Phase 3 Cyclooxygenase inhibitor
- Pravastatin
- Phase 3 HMG-CoA reductase inhibitor
- Labetalol
- Phase 3 Adrenergic receptor antagonist
- Esomeprazole
- Phase 3 Potassium-transporting ATPase inhibitor
- Metformin
- Phase 3 Mitochondrial complex I (NADH dehydrogenase) inhibitor
- Misoprostol
- Phase 3 Prostanoid EP3 receptor agonist
- Furosemide
- Phase 3 Sodium-(potassium)-chloride cotransporter 2 inhibitor
- Lidocaine
- Phase 3 Sodium channel alpha subunit blocker
- Ephedrine
- Phase 3 Adrenergic receptor agonist
- Hydrochlorothiazide
- Phase 3 Thiazide-sensitive sodium-chloride cotransporter inhibitor
- Hydroxychloroquine
- Phase 3 Ferriprotoporphyrin IX inhibitor
- Atorvastatin
- Phase 3 HMG-CoA reductase inhibitor
- Metaraminol
- Phase 3 Adrenergic receptor alpha-1 agonist
- Nifedipine
- Phase 3 Voltage-gated L-type calcium channel blocker
- Nicardipine
- Phase 3 Voltage-gated L-type calcium channel blocker
- Antithrombin alfa
- Phase 3 Coagulation factor X inhibitor
- Ubidecarenone
- Phase 3 Supplement
- Urapidil
- Phase 3
- Antithrombin gamma
- Phase 3
- Sildenafil
- Phase 2 Phosphodiesterase 5A inhibitor
- Dexmedetomidine
- Phase 2 Adrenergic receptor alpha-2 agonist
- Ascorbic acid
- Phase 2 Supplement
- Niacinamide
- Phase 2
- Acetaminophen
- Phase 2 Cyclooxygenase inhibitor
- Celecoxib
- Phase 2 Cyclooxygenase-2 inhibitor
- Enalapril
- Phase 2 Angiotensin-converting enzyme inhibitor
- Ibuprofen
- Phase 2 Cyclooxygenase inhibitor
- Ketorolac
- Phase 2 Cyclooxygenase inhibitor
- Oxycodone
- Phase 2 Mu opioid receptor agonist
- Progesterone
- Phase 2 Progesterone receptor agonist
Showing the 30 furthest along of 42 in trials.
How Its Trials Ended
765 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 102 whose ending is known, 25% met their primary endpoint, 19% missed it and 56% stopped early.
- Completed, result not reported32042%
- Ongoing18224%
- Status unknown16121%
- Stopped: other or unclear324%
- Met its primary endpoint263%
- Missed its primary endpoint192%
- Stopped: enrollment or feasibility182%
- Stopped: lack of efficacy30%
- Stopped: sponsor or business decision30%
- Stopped: safety10%
Trials Authorized in Canada
Newest first; search them all in Canada trials| Mar 3, 2026 | A phase 2, open-label dose-escalation and expansion study of dm199 in early-onset preeclampsia under expectant managementDM199 (rinvecalinase alfa) | Diamedica Inc | Pending |
| Dec 5, 2013 | Essai randomisé comparant leffet de laspirine à faible dose au placebo sur le poids de naissance des grossesses gémellaires (étude gap)Acetylsalicylic acid | Centre Hospitalier Affilié Universitaire De QuéBec | Pending |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA